Compare TCBK & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TCBK | DFTX |
|---|---|---|
| Founded | 1975 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 1995 | N/A |
| Metric | TCBK | DFTX |
|---|---|---|
| Price | $49.12 | $22.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $53.80 | $38.50 |
| AVG Volume (30 Days) | 100.2K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ 6.94 | N/A |
| EPS | ★ 3.70 | N/A |
| Revenue | ★ $53,445,000.00 | N/A |
| Revenue This Year | $12.03 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $13.69 | ★ N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $37.80 | $14.62 |
| 52 Week High | $53.18 | $26.25 |
| Indicator | TCBK | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.27 | 60.63 |
| Support Level | $48.06 | $16.37 |
| Resistance Level | $51.15 | N/A |
| Average True Range (ATR) | 1.07 | 1.39 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 28.81 | 40.92 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).